NSE: POLYMED | BSE: 531768

Expensive Performer

Download real time

1509.00 -1.90 (-0.13%)

34.86% Fall from 52W High

22,916 NSE+BSE Volume

NSE 16 Jun, 2026 12:17 PM (IST)

15,295.1

Market Cap

Market Leader

Beta 1Year

Low volatility

Poly Medicure Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for POLYMED, BSE:531768 Poly Medicure Ltd.

Search Inside the pdf :

Poly Medicure Ltd.

17 Mar 2026

1509.00

-0.13%

Poly Medicure Ltd.

Buy: Poly Medicure Ltd.

Joindre Capital Services

It is a medical devices company with a product portfolio comprised of 225+ medical devices across 13 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others, supported by a robust distribution network of 950+ distributors across India and globally,...

Poly Medicure Ltd. is trading below its 150 day SMA of 1569.5

Poly Medicure Ltd.

27 Dec 2024

1509.00

-0.13%

POLY MEDICURE LIMITED

Buy: Poly Medicure Ltd.

FundsIndia

Poly Medicure Ltd. has an average target of 1489.20 from 1 broker.

Poly Medicure Ltd.

25 Jul 2024

1509.00

-0.13%

Fresh capacity and exports to drive momentum

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (PolyMed) Q1FY25 performance was boosted by exports (~23% YoY) while domestic business growth (~12% YoY) took a pause on high base. The company has commissioned four new plants that may double its device manufacturing capacity to 1.8bn units p.a by FY25 end.

Poly Medicure Ltd. is trading below its 150 day SMA of 1569.5

Poly Medicure Ltd.

09 Aug 2023

1509.00

-0.13%

Strong all-round performance

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure reported its all-time high revenues and EBITDA in Q1FY24 driven by solid performance across India (30% YoY growth) and Europe (35%). Softening of raw material prices fuelled a 220bps jump in gross margin. Ahead EBITDA margin is likely to be between 25-27%. Company will commercialise 4 manufacturing facilities in FY24 and launch 10-12 products in critical care segment, which will also likely drive growth and aid margin expansion.

Poly Medicure Ltd. is trading above its 100 day SMA of 1426.4

Poly Medicure Ltd.

30 Jan 2023

1509.00

-0.13%

Growth sustains; margin expands

Accumulate: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q3FY23 performance beats our estimates on all fronts. Revenue grew 23.7% YoY to Rs2.8bn (I-Sec: Rs2.7bn) led by strong demand across segments. EBITDA margin improved 270bps YoY and 140bps QoQ to 24.9%, supported by strong gross margin expansion.

Poly Medicure has lost -32.05% in the last 1 Year

Poly Medicure Ltd.

08 Nov 2022

1509.00

-0.13%

Strong print

Hold: Poly Medicure Ltd.

Recommendation Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q2FY23 performance beats our estimates on all fronts.
Revenue grew 23.0% YoY to Rs2.7bn (I-Sec: Rs2.6bn) led by strong demand across segments.